CASI Pharmaceuticals (CASI) Short-Term Debt to Equity

The price chart for CASI Pharmaceuticals (CASI) serves as an indicator for a business that introduces advanced anti-tumor agents to the PRC, minimizing R&D costs through licensing. Yields and capital inflows here depend on government drug subsidies in China, which determine the level of the 0.00 metric. The company's growth is driven by a strategic alliance with Western biopharma partners for the joint promotion of therapies.

CASI - CASI Pharmaceuticals Short-Term Debt to Equity Ratio over the range 07/04/2022 - 03/14/2026

Financial and market metric breakdowns for CASI Pharmaceuticals, Inc (CASI)

- stock quotes and analyst forecast:

Stock Price CASI Pharmaceuticals|CASI - Analyst Consensus Forecast

- market capitalization details:

Market Value CASI Pharmaceuticals Inc.|CASI - Business Value

- balance sheet equity data:

Book Value per Share CASI Pharmaceuticals|CASI - Company Net Assets|Market Capitalization to Book Value Ratio casipharmaceuticals.com|CASI - Company Assets

- business debt structure and liquidity details:

Debt to Equity CASI Pharmaceuticals|CASI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio CASI Pharmaceuticals|CASI - Aggregate Debt Obligations|Debts to Book Capitalization CASI Pharmaceuticals Inc.|CASI - Company Long-Term Debt|Company Short-Term Debt CASI Pharmaceuticals

Fundamental valuation:CASI Pharmaceuticals, Inc.

Signature product of casipharmaceuticals.com

The specifics of the CASI Pharmaceuticals (CASI) pharmaceutical business, characterized by costly research and regulatory pressure, make the current level of short-term debt to equity a critical liquidity marker. The short-term liabilities to equity ratio demonstrates the company's dependence on rapid refinancing; while reducing this ratio minimizes default risk, excessive conservatism in borrowing may slow the pace of commercializing new drugs.

Competing companies